|
1
|
Anand R, Gill KD and Mahdi AA:
Therapeutics of Alzheimer's disease: Past, present and future.
Neuropharmacology. 76:27–50. 2014.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Alzheimer's Association: 2018 Alzheimer's
disease facts and figures. Alzheimer Dement 14: 367-429, 2018.
|
|
3
|
Lombardo S and Maskos U: Role of the
nicotinic acetylcholine receptor in Alzheimer's disease pathology
and treatment. Neuropharmacology. 96:255–262. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Birks JS, Chong LY and Grimley Evans J:
Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev.
9(CD001191)2015.(Epub ahead of print). PubMed/NCBI View Article : Google Scholar
|
|
5
|
Islam MM, Gurung AB, Bhattacharjee A,
Aguan K and Mitra S: Human serum albumin reduces the potency of
acetylcholinesterase inhibitor based drugs for Alzheimer's disease.
Chem Biol Interact. 249:1–9. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Tsoi KK, Chan JY, Leung NW, Hirai HW, Wong
SY and Kwok TC: Combination therapy showed limited superiority over
monotherapy for Alzheimer disease: A meta-analysis of 14 randomized
trials. J Am Med Dir Assoc. 17:863.e1–e8. 2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
D'onofrio G, Sancarlo D, Addante F,
Ciccone F, Cascavilla L, Paris F, Elia AC, Nuzzaci C, Picoco M,
Greco A, et al: A pilot randomized controlled trial evaluating an
integrated treatment of rivastigmine transdermal patch and
cognitive stimulation in patients with Alzheimer's disease. Int J
Geriatr Psychiatry. 30:965–975. 2015.PubMed/NCBI View
Article : Google Scholar
|
|
8
|
Han HJ, Kwon JC, Kim JE, Kim SG, Park JM,
Park KW, Park KC, Park KH, Moon SY, Seo SW, et al: Effect of
rivastigmine or memantine add-on therapy is affected by
butyrylcholinesterase genotype in patients with probable
Alzheimer's disease. Eur Neurol. 73:23–28. 2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Birks JS and Grimley Evans J: Rivastigmine
for Alzheimer's disease. Cochrane Database Syst Rev.
2015(CD001191)2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Maher-Edwards G, Dixon R, Hunter J, Gold
M, Hopton G, Jacobs G, Hunter J and Williams P: SB-742457 and
donepezil in Alzheimer disease: A randomized, placebo-controlled
study. Int J Geriatr Psychiatry. 26:536–544. 2011.PubMed/NCBI View
Article : Google Scholar
|
|
11
|
Nokkari A, Abou-El-Hassan H, Mechref Y,
Mondello S, Kindy MS, Jaffa AA and Kobeissy F: Implication of the
Kallikrein-Kinin system in neurological disorders: Quest for
potential biomarkers and mechanisms. Prog Neurobiol. 165-167:26–50.
2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Zhao WQ and Alkon DL: Alzheimer's disease
diagnosis based on mitogen-activated protein kinase
phosphorylation. U.S. Pat Appl. 9:188–595. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Ni R, Kindler DR, Waag R, Rouault M,
Ravikumar P, Nitsch R, Rudin M, Camici GG, Liberale L, Kulic L and
Klohs J: fMRI reveals mitigation of cerebrovascular dysfunction by
bradykinin receptors 1 and 2 inhibitor noscapine in a mouse model
of cerebral amyloidosis. Front Aging Neurosci.
11(27)2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Makitani K, Nakagawa S, Izumi Y, Akaike A
and Kume T: Inhibitory effect of donepezil on bradykinin-induced
increase in the intracellular calcium concentration in cultured
cortical astrocytes. J Pharmacol Sci. 134:37–44. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
McKhann GM, Knopman DS, Chertkow H, Hyman
BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux
R, et al: The diagnosis of dementia due to Alzheimer's disease:
Recommendations from the National Institute on Aging-Alzheimer's
Association workgroups on diagnostic guidelines for Alzheimer's
disease. Alzheimers Dement. 7:263–269. 2011.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Arevalo-Rodriguez I, Smailagic N, Roqué I
Figuls M, Ciapponi A, Sanchez-Perez E, Giannakou A, Pedraza OL,
Bonfill Cosp X and Cullum S: Mini-mental state examination (MMSE)
for the detection of Alzheimer's disease and other dementias in
people with mild cognitive impairment (MCI). Cochrane Database Syst
Rev. 2015(CD010783)2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Blessed G, Tomlinson BE and Roth M:
Blessed-Roth dementia scale (DS). Psychopharmacol Bull. 24:705–708.
1988.PubMed/NCBI
|
|
18
|
Podhorna J, Krahnke T, Shear M and
Harrison JE: Alzheimer's Disease Neuroimaging Initiative:
Alzheimer's disease assessment scale-cognitive subscale variants in
mild cognitive impairment and mild Alzheimer's disease: Change over
time and the effect of enrichment strategies. Alzheimers Res Ther.
8(8)2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Logsdon RG, Gibbons LE, McCurry SM and
Teri L: Quality of life in Alzheimer's disease: Patient and
caregiver reports. J Ment health Aging. 5:21–32. 1999.
|
|
20
|
Winblad B, Amouyel P, Andrieu S, Ballard
C, Brayne C, Brodaty H, Cedazo-Minguez A, Dubois B, Edvardsson D,
Feldman H, et al: Defeating Alzheimer's disease and other
dementias: A priority for European science and society. Lancet
Neurol. 15:455–532. 2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Cummings J, Aisen PS, DuBois B, Frölich L,
Jack CR Jr, Jones RW, Morris JC, Raskin J, Dowsett SA and Scheltens
P: Drug development in Alzheimer's disease: The path to 2025.
Alzheimers Res Ther. 8(39)2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Shao ZQ: Comparison of the efficacy of
four cholinesterase inhibitors in combination with memantine for
the treatment of Alzheimer's disease. Int J Clin Exp Med.
8:2944–2948. 2015.PubMed/NCBI
|
|
23
|
Godyń J, Jończyk J, Panek D and Malawska
B: Therapeutic strategies for Alzheimer's disease in clinical
trials. Pharmacol Rep. 68:127–138. 2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Chase TN, Farlow MR and Clarence-Smith K:
Donepezil plus Solifenacin (CPC-201) treatment for Alzheimer's
disease. Neurotherapeutics. 14:405–416. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Kearney MC, Caffarel-Salvador E, Fallows
SJ, McCarthy HO and Donnelly RF: Microneedle-mediated delivery of
donepezil: Potential for improved treatment options in Alzheimer's
disease. Eur J Pharm Biopharm. 103:43–50. 2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Mohamed LA, Keller JN and Kaddoumi A: Role
of P-glycoprotein in mediating rivastigmine effect on amyloid-β
brain load and related pathology in Alzheimer's disease mouse
model. Biochim Biophys Acta. 1862:778–787. 2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Oh YS, Kim JS and Lee PH: Effect of
rivastigmine on behavioral and psychiatric symptoms of Parkinson's
disease dementia. J Mov Disord. 8:98–102. 2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Cummings J, Lai TJ, Hemrungrojn S,
Mohandas E, Yun Kim S, Nair G and Dash A: Role of donepezil in the
management of neuropsychiatric symptoms in Alzheimer's disease and
dementia with Lewy bodies. CNS Neurosci Ther. 22:159–166.
2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Nieto RA, Deardorff WJ and Grossberg GT:
Efficacy of rivastigmine tartrate, transdermal system, in
Alzheimer's disease. Expert Opin Pharmacother. 17:861–870.
2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Montero-Odasso M, Muir-Hunter SW,
Oteng-Amoako A, Gopaul K, Islam A, Borrie M, Wells J and Speechley
M: Donepezil improves gait performance in older adults with mild
Alzheimer's disease: A phase II clinical trial. J Alzheimers Dis.
43:193–199. 2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Bitencourt RM, Guerra de Souza AC, Bicca
MA, Pamplona FA, de Mello N, Passos GF, Medeiros R, Takahashi RN,
Calixto JB and Prediger RD: Blockade of hippocampal bradykinin B1
receptors improves spatial learning and memory deficits in
middle-aged rats. Behav Brain Res. 316:74–81. 2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Asraf K, Torika N, Danon A and
Fleisher-Berkovich S: Involvement of the bradykinin B1
receptor in microglial activation: In vitro and in vivo studies.
Front Endocrinol (Lausanne). 8(82)2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Bicca MA, Costa R, Loch-Neckel G,
Figueiredo CP, Medeiros R and Calixto JB: B2 receptor
blockage prevents Aβ-induced cognitive impairment by
neuroinflammation inhibition. Behav Brain Res. 278:482–491.
2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Ashby EL, Love S and Kehoe PG: Assessment
of activation of the plasma kallikrein-kinin system in frontal and
temporal cortex in Alzheimer's disease and vascular dementia.
Neurobiol Aging. 33:1345–1355. 2012.PubMed/NCBI View Article : Google Scholar
|
